SELLAS Life Sciences Group (NASDAQ:SLS) Reaches New 1-Year High – Here’s What Happened

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) shares reached a new 52-week high on Monday . The stock traded as high as $5.94 and last traded at $5.9240, with a volume of 5409885 shares changing hands. The stock had previously closed at $5.53.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $7.00.

SELLAS Life Sciences Group Price Performance

The firm’s 50-day moving average price is $4.27 and its 200-day moving average price is $2.72. The stock has a market cap of $783.99 million, a P/E ratio of -19.70 and a beta of 2.18.

Institutional Trading of SELLAS Life Sciences Group

Several hedge funds have recently bought and sold shares of the stock. ProShare Advisors LLC bought a new stake in SELLAS Life Sciences Group in the 2nd quarter worth approximately $43,000. Geode Capital Management LLC grew its holdings in shares of SELLAS Life Sciences Group by 168.2% in the second quarter. Geode Capital Management LLC now owns 2,200,428 shares of the company’s stock valued at $4,819,000 after purchasing an additional 1,379,988 shares in the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of SELLAS Life Sciences Group in the second quarter valued at $51,000. Intech Investment Management LLC bought a new stake in SELLAS Life Sciences Group in the second quarter worth $101,000. Finally, JPMorgan Chase & Co. purchased a new stake in SELLAS Life Sciences Group during the second quarter valued at $136,000. Hedge funds and other institutional investors own 17.38% of the company’s stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.